Structure−Activity Relationships of Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone. 3. Effect of Replacing the Inner Polymethylene Chain with Cyclic Moieties

• Published in: Journal of medicinal chemistry 2004-12, Vol.47 (26), p.6490-6498
• Main Authors: Tumiatti, Vincenzo, Andrisano, Vincenza, Banzi, Rita, Bartolini, Manuela, Minarini, Anna, Rosini, Michela, Melchiorre, Carlo
• Format: Article
• Language: English
• Subjects: Acetylcholinesterase - chemistry; Amyloid beta-Peptides - chemistry; Biological and medical sciences; Butyrylcholinesterase - chemistry; Catecholaminergic system; Cholinesterase Inhibitors - chemical synthesis; Cholinesterase Inhibitors - chemistry; Humans; Medical sciences; Neuropharmacology; Neurotransmitters. Neurotransmission. Receptors; Pharmacology. Drug treatments; Piperidines - chemical synthesis; Piperidines - chemistry; Polyamines - chemical synthesis; Polyamines - chemistry; Structure-Activity Relationship
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/jm0494366

In the present paper we expanded SAR studies of 3, the ethyl analogue of the AChE inhibitor caproctamine (2), by investigating the role of its octamethylene spacer separating the two amide functions through the replacement with dipiperidine and dianiline moieties. Compounds 4 and 8 were the most interesting of the two series of compounds. Compound 4 was the most potent AChE inhibitor with a pIC50 value of 8.48 ± 0.02, while displaying also significant muscarinic M2 antagonistic activity (pK b value of 6.18 ± 0.20). The availability of a suitable assay allowed us to verify whether 2, 3, 4, and 8 inhibit AChE-induced Aβ aggregation. Although all four derivatives caused a mixed type of AChE inhibition (active site and PAS), only 4 and 8, which bear an inner constrained spacer, were able to inhibit AChE-induced Aβ aggregation to a greater extent than donepezil. Clearly, the ability of an AChE inhibitor, based on a linear polyamine backbone, to bind both AChE sites may not be a sufficient condition to inhibit also AChE-induced Aβ aggregation. Dipiperidine derivative 4 emerged as a valuable pharmacological tool and a promising lead compound for new ligands to investigate and, hopefully, treat Alzheimer's disease.